State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China.
Department of oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
FASEB J. 2024 Mar 15;38(5):e23523. doi: 10.1096/fj.202301161R.
Zinc and ring finger 3 (ZNRF3) is a negative suppressor of Wnt signal and newly identified as an important regulator in tumorigenesis and development. However, the pan-cancer analysis of ZNRF3 has not been reported. We found that ZNRF3 was significantly decreased in six tumors including CESC, KIRP, KIRC, SKCM, OV, and ACC, but increased in twelve tumors, namely LGG, ESCA, STES, COAD, STAD, LUSC, LIHC, THCA, READ, PAAD, TGCT, and LAML. Clinical outcomes of cancer patients were closely related to ZNRF3 expression in ESCA, GBM, KIRC, LUAD, STAD, UCEC, LGG, and SARC. The highest genetic alteration frequency of ZNRF3 occurred in ACC. Abnormal expression of ZNRF3 could be attributed to the differences of copy number variation (CNV) and DNA methylation as well as ZNRF3-interacting proteins. Besides, ZNRF3 were strongly associated with tumor heterogeneity, tumor stemness, immune score, stromal score and ESTIMATE score in certain cancers. In terms of immune cell infiltration, ZNRF3 was positively correlated to infiltration of cancer-associated fibroblasts in CESC, HNSC, OV, PAAD, PRAD, and THYM, but negatively associated with infiltration of CD8 T cells in HNSC, KIRC, KIRP and THYM. Moreover, ZNRF3 expression was correlated with most immune checkpoint genes in SARC, LUSC, LUAD, PRAD, THCA, UVM, TGCT, and OV, and associated with overwhelming majority of immunoregulatory genes in almost all cancers. Most RNA modification genes were also remarkably related to ZNRF3 level in KIRP, LUAD, LUSC, THYM, UVM, PRAD, and UCEC, indicating that ZNRF3 might have an important effect on cancer epigenetic regulation. Finally, we verified the expression and role of ZNRF3 in clinical specimens and cell lines of renal cancer and liver cancer. This study provides a comprehensive pan-cancer analysis of ZNRF3 and reveals the complexity of its carcinogenic effect.
锌指蛋白 3(ZNRF3)是 Wnt 信号的阴性抑制剂,新近被鉴定为肿瘤发生和发展的重要调节剂。然而,ZNRF3 的泛癌分析尚未报道。我们发现,ZNRF3 在包括 CESC、KIRP、KIRC、SKCM、OV 和 ACC 在内的六种肿瘤中显著降低,但在十二种肿瘤中增加,即 LGG、ESCA、STES、COAD、STAD、LUSC、LIHC、THCA、READ、PAAD、TGCT 和 LAML。癌症患者的临床结局与 ESCA、GBM、KIRC、LUAD、STAD、UCEC、LGG 和 SARC 中 ZNRF3 的表达密切相关。ZNRF3 的最高遗传改变频率发生在 ACC。ZNRF3 的异常表达可归因于拷贝数变异(CNV)和 DNA 甲基化以及与 ZNRF3 相互作用的蛋白质的差异。此外,ZNRF3 与某些癌症中的肿瘤异质性、肿瘤干性、免疫评分、基质评分和 ESTIMATE 评分密切相关。在免疫细胞浸润方面,ZNRF3 与 CESC、HNSC、OV、PAAD、PRAD 和 THYM 中的癌症相关成纤维细胞浸润呈正相关,与 HNSC、KIRC、KIRP 和 THYM 中的 CD8 T 细胞浸润呈负相关。此外,ZNRF3 表达与 SARC、LUSC、LUAD、PRAD、THCA、UVM、TGCT 和 OV 中的大多数免疫检查点基因相关,并与几乎所有癌症中的绝大多数免疫调节基因相关。大多数 RNA 修饰基因也与 KIRP、LUAD、LUSC、THYM、UVM、PRAD 和 UCEC 中的 ZNRF3 水平显著相关,表明 ZNRF3 可能对癌症表观遗传调控有重要影响。最后,我们在肾癌和肝癌的临床标本和细胞系中验证了 ZNRF3 的表达和作用。本研究对 ZNRF3 进行了全面的泛癌分析,揭示了其致癌作用的复杂性。